FDG-PET imaging in HIV infection and tuberculosis

Seminars in Nuclear Medicine

Volumn 43, Issue 5, 2013, Pages 349-366

  Sathekge, Mike ^a   Maes, Alex ^a,b,c   Wiele, Christophe Van De ^a,d  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b AZ Groeninge ^*  (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUORODEOXYGLUCOSE F 18;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; ARTICLE; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTRAPULMONARY TUBERCULOSIS; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; INFECTION CONTROL; KAPOSI SARCOMA; LIPODYSTROPHY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG TUBERCULOSIS; LYMPHOMA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PYREXIA IDIOPATHICA; UTERINE CERVIX CANCER;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HIV INFECTIONS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TUBERCULOSIS; WHOLE BODY IMAGING;

EID: 84881085954     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2013.04.008     Document Type: Article

References (145)

1. UNAIDS. Together We Will End AIDS. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012. http://www.unaids.org/en/ resources/campaigns/togetherwewillendaids/
2. WHO. Global Tuberculosis Control 2011. Geneva, Switzerland: World Health Organization; 2011. http://www.who.int/tb/publications/global-report/2011/ gtbr11-full.pdf
3. + T cells as targets and effectors in the pathogenesis of primary HIV infection Curr HIV/AIDS Rep 3 2006 5 12
4. R. Samuel, R. Bettiker, and B. Suh AIDS related opportunistic infections, going but not gone Arch Pharm Res 25 2002 215 228
5. M. Cadogan, and A. Dalgleish HIV induced AIDS and related cancers: Chronic immune activation and future therapeutic strategies Adv Cancer Res 101 2008 349 395
6. Y. Aoki, and G. Tosato Neoplastic conditions in the context of HIV-1 infection Curr HIV Res 2 2004 343 349
7. C. Porter, J. Laditka, and C. Cornman Prevalence of AIDS dementia complex: Results from a state-wide population-based registry of Alzheimer's disease and related disorders J S C Med Assoc 104 2008 223 236
8. K. Naidoo, C. Baxter, and S.S. Abdool Karim Antiretroviral therapy during tuberculosis treatment Curr Opin Infect Dis 26 2013 35 42
9. F.J. Palella Jr, R.K. Baker, and A.C. Moorman Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study J Acquir Immune Defic Syndr 43 2006 27 34
10. C.A. Sabin, C.J. Smith, and M. Youle Deaths in the era of HAART: Contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers AIDS 20 2006 67 71
11. C. Smit, R. Geskus, and S. Walker Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion AIDS 20 2006 741 749
12. N.F. Crum, R.H. Riffenburgh, and S. Wegner Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras J Acquir Immune Defic Syndr 41 2006 194 200
13. C. Lewden, T. May, and E. Rosenthal Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr 48 2008 590 598
14. F. Bonnet, C. Lewden, and T. May Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France Scand J Infect Dis 37 2005 482 487
15. H.B. Krentz, G. Kliewer, and M.J. Gill Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003 HIV Med 6 2005 99 106
16. C.H. Yang, Y.F. Huang, and C.F. Hsiao Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005 HIV Med 9 2008 535 543
17. G. El-Haddad, H. Zhuang, and N. Gupta Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders Semin Nucl Med 34 2004 313 329
18. R. Kubota, K. Kubota, and S. Yamada Microautoradiolgraphic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake J Nucl Med 35 1994 104 112
19. M. Miceli, R. Atoui, and R. Walker Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: A preliminary report J Clin Oncol 22 2004 1949 1956
20. 18F- fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: A study of 165 infectious episodes J Clin Oncol 23 2005 7857 7863
21. M. Cloyd, J. Chen, and I. Wang How does HIV cause AIDS? The homing theory Mol Med Today 6 2000 108 111
22. M. Lederman, and L. Margolis The lymph node in HIV pathogenesis Semin Immunol 20 2008 187 195
23. S. Bakheet, and J. Powe Benign causes of 18-FDG uptake on whole-body imaging Semin Nucl Med 28 2000 352 358
24. R. Brown, J. Leung, and S. Fisher Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: Are inflammatory cells important? J Nucl Med 36 1995 1854 1861
25. R. Kubota, S. Yamada, and K. Kubota Intratumoral distribution of fluorine-18-deoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography J Nucl Med 33 1992 1972 1980
26. M. Bental, and C. Deutsch Metabolic changes in activated Tcells: An NMR study of human peripheral blood lymphocytes Magn Reson Med 29 1993 317 326
27. S. Marjanovic, S. Skog, and T. Heiden Expression of glycolytic isoenzymes in activated human peripheral lymphocytes: Cell cycle analysis using flow cytometry Exp Cell Res 193 1991 425 431
28. 18F-fluro-2-deoxyglucose positron emission tomography in healthy subjects Anticancer Res 21 2001 701 706
29. A. Scharko, S. Perlman, and P. Hinds Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques Proc Natl Acad Sci U S A 93 1996 6425 6430
30. M. Wallace, R. Pyzalski, and D. Horejsh Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques Virology 274 2000 255 261
31. A. Scharko, S. Perlman, and R. Pyzalski Whole-body positron emission tomography in patients with HIV-1 infection Lancet 20 2003 959 961
32. S. Iyengar, B. Chin, and J. Margolick Anatomical loci of HIV-associated immune activation and association with viraemia Lancet 20 2003 945 950
33. M. Sathekge, A. Maes, and M. Kgomo Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 cell count Nucl Med Commun 31 2010 137 140
34. D. Brust, M. Polis, and R. Davey Fluorodeoxyglucose imaging in healthy subjects with HIV infection: Impact of disease stage and therapy on pattern of nodal activation AIDS 20 2006 495 503
35. Y. Liu Clinical significance of diffusely increased splenic uptake on FDG-PET Nucl Med Commun 30 2009 763 769
36. G. Lucignani, E. Orunesu, and M. Cesari FDG-PET imaging in HIV-infected subjects: Relation with therapy and immunovirological variables Eur J Nucl Med Mol Imaging 36 2009 640 647
37. D.T. Durack, and A.C. Street Fever of unknown origin - Reexamined and redefined Curr Clin Top Infect Dis 11 1991 35 51
38. D.C. Knockaert, S. Vanderschueren, and D. Blockmans Fever of unknown origin in adults: 40 years on J Intern Med 253 2003 263 275
39. T. Schacker, A.C. Collier, and J. Hughes Clinical and epidemiologic features of primary HIV infection Ann Intern Med 125 1996 257 264
40. P. De Munter, W.E. Peetermans, and I. Derdelinckx Fever in HIV-infected patients: Less frequent but still complex Acta Clin Belg 67 2012 276 281
41. P.P. Koopmans, and D.M. Burger Managing drug reactions to sulfonamides and other drugs in HIV infection: Desensitization rather than rechallenge? Pharm World Sci 20 1998 253 257
42. E.G. Bing, M.A. Burnam, and D. Longshore Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States Arch Gen Psychiatry 58 2001 721 728
43. C.P. Bleeker-Rovers, J.W. van der Meer, and W.J. Oyen Fever of unknown origin Semin Nucl Med 39 2009 81 87
44. 18F-FDGPET/CT J Nucl Med 49 2008 1980 1985
45. A.W.J.M. Glaudemans, and A. Signore FDG-PET/CT in infections: The imaging method of choice? Eur J Nucl Med Mol Imaging 37 2010 1986 1991
46. C. Martin, C. Castaigne, and M. Tondeur Role and interpretation of FDG-PET/CT in HIV patients with fever of unknown origin: A prospective study J Int AIDS Soc 15 suppl 4 2012 18107
47. F. Bonnet, and G. Chêne Evolving epidemiology of malignancies in HIV Curr Opin Oncol 20 2008 534 540
48. T. Powles, D. Robinson, and J. Stebbing Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection J Clin Oncol 27 2008 884 890
49. A.E. Grulich, M.T. van Leeuwen, and M.O. Falster Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis Lancet 370 2007 59 67
50. R. Bedimo Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era Curr HIV/AIDS Rep 5 2008 140 149
51. N. Crum-Cianflone, K. Hullsiek, and V. Marconi Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: A 20-year cohort study AIDS 2 23 2009 41 50
52. A. Mayor, M. Gomez, and E. Rios-Olivares AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy Ethn Dis 18 S2 2008 189 194
53. A. Chitale Cancer and AIDS: Indian J Pathol Microbiol 48 2005 151 160
54. M. Moodley, and S. Mould Invasive cervical cancer and human immunodeficiency virus (HIV) infection in KwaZulu-Natal, South Africa J Obstet Gynecol 25 2005 706 710
55. E.A. Kidd, and P.W. Grigsby Intratumoral metabolic heterogeneity of cervical cancer Clin Cancer Res 14 2008 5236 5241
56. M.H. Einstein, and R. Phaeton Issues in cervical cancer incidence and treatment in HIV Curr Opin Oncol 22 2010 449 455
57. P.W. Grigsby Role of PET in gynecologic malignancy Curr Opin Oncol 21 2009 420 424
58. E.A. Kidd, I. El Naqa, and B.A. Siegel FDG-PET-based prognostic nomograms for locally advanced cervical cancer Gynecol Oncol 127 2012 136 140
59. E.J. Schwartz, R.F. Dorfman, and S. Kohler Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: An immunohistochemical study of 16 cases Am J Surg Pathol 27 2003 1546 1550
60. R. Sullivan, B.J. Dezube, and H.B. Koon Signal transduction targets in Kaposi's sarcoma Curr Opin Oncol 18 2006 456 462
61. M. Bower, C. Palmieri, and T. Dhillon AIDS-related malignancies: Changing epidemiology and the impact of highly active antiretroviral therapy Curr Opin Infect Dis 19 2006 14 19
62. A. van de Luijtgaarden, A. van der Ven, and W. Leenders Imaging of HIV-associated Kaposi sarcoma. F-18-FDG-PET/CT and In-111- bevacizumabscintigraphy J AIDS 54 2010 444 446
63. 18F- fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy Jpn J Radiol 28 2010 759 762
64. S.E. Krown, M.A. Testa, and J. Huang AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee J Clin Oncol 15 1997 3085 3092
65. N. Dupin, T.L. Diss, and P. Kellam HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma Blood 95 2000 1406 1412
66. R. Barker, F. Kazmi, and J. Stebbing FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease Eur J Nucl Med Mol Imaging 36 2009 648 652
67. E.A. Engels, R.M. Pfeiffer, and J.J. Goedert Trends in cancer risk among people with AIDS in the United States 1980-2002 AIDS 20 2006 1645
68. C. Diamond, T.H. Taylor, and T. Aboumrad Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy Cancer 106 2005 128 135
69. E.A. Engels, R.M. Pfeiffer, and O. Landgren Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era J Acquir Immune Defic Syndr 54 2010 78 84
70. M. Guiguet, F. Boué, and J. Cadranel Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study Lancet Oncol 10 2009 1152 1159
71. A. Zoufaly, H.J. Stellbrink, and M.A. Heiden Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma J Infect Dis 200 2009 79 87
72. M. Guech-Ongey, E.P. Simard, and W.F. Anderson AIDS-related Burkitt lymphoma in the United States: What do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 116 2010 5600 5604
73. J. Gabarre, M. Raphael, and E. Lepage Human immunodeficiency virus-related lymphoma: Relation between clinical features and histologic subtypes Am J Med 111 2001 704 711
74. P.A. Forsyth, and L.M. DeAngelis Biology and management of AIDS-associated primary CNS lymphomas Hematol Oncol Clin North Am 10 1996 1125 1134
75. S. Franceschi, M. Lise, and G.M. Clifford Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study Br J Cancer 103 2010 416 422
76. Y. Liu Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT Ann Nucl Med 25 2011 536 546
77. E. Goshen, T. Davidson, and A. Avigdor PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads Clin Nucl Med 33 2008 610 614
78. M. Sathekge, A. Maes, and M. Kgomo FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: Implications for cancer staging Q J Nucl Med Mol Imaging 54 2010 698 703
79. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma Aids Patient Care STDS 22 2008 695 700
80. H. Martis, and N. Mounier Hodgkin lymphoma in patients with HIV infection: A review Curr Hematol Malig Rep 7 2012 228 234
81. J.M. Hoffman, H.A. Waskin, and T. Schifter FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS J Nucl Med 34 1993 567 575
82. K. Villringer, H. Jager, and M. Dichgans Differential diagnosis of CNS lesions in AIDS patients by FDG-PET J Comput Assist Tomogr 19 1995 532 536
83. A. Heald, J.M. Hoffman, and J. Bartlett Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET) Int J STD AIDS 7 1996 337 346
84. M. O'Doherty, S. Barrington, and M. Campbell PET scanning and the human immunodeficiency virus-positive patient J Nucl Med 38 1997 1575 1583
85. S.P. Woods, D.J. Moore, and E. Weber Cognitive neuropsychology of HIV-associated neurocognitive disorders Neuropsychol Rev 19 2009 152 1568
86. D.A. Hammoud, J.M. Hoffmann, and M.G. Pomper Molecular neuroimaging: From conventional to emerging techniques1 Radiology 24 2007 21 42
87. M. Boska, R. Mosley, and M. Nawab Advances in neuroimaging for HIV-1 associated neurological dysfunction: Clues to the diagnosis, pathogenesis and therapeutic monitoring Curr HIV Res 2 2004 61 78
88. G. Depas, C. Chiron, and M. Tardieu Functional brain imaging in HIV-1-infected children born to seropositive mothers J Nucl Med 36 1995 2169 2174
89. C. Hinkin, W. Van Gorp, and M. Mandelkern Cerebral metabolic change in patients with AIDS: Report of a six-month follow-up using positron-emission tomography J Neuropsychiatry Clin Neurosci 7 1995 180 187
90. T. Newton, A. Leuchter, and D. Walter EEG coherence in men with AIDS: Association with subcortical metabolic activity J Neuropsychiatry Clin Neurosci 5 1993 316 321
91. D. Rottenberg, J. Sidtis, and S. Strother Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia J Nucl Med 37 1996 1133 1141
92. V. Villemagne, R. Phillips, and X. Liu Peptide T and glucose metabolism in AIDS dementia complex J Nucl Med 37 1996 1177 1180
93. H. von Giesen, C. Antke, and H. Hefter Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: Electrophysiologic and positron emission tomography findings Arch Neurol 57 2000 1601 1607
94. D. Rottenberg, J. Moeller, and S. Strother The metabolic pathology of the AIDS dementia complex Ann Neurol 22 1987 700 706
95. W. Van Gorp, M. Mandelkern, and M. Gee Cerebral metabolic dysfunction in AIDS: Findings in a sample with and without dementia J Neuropsychiatry Clin Neurosci 4 1992 280 287
96. L.A. Kingsley, J. Cuervo-Rojasc, and A. Muñoz Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study AIDS 22 2008 1589 1599
97. J.V. Baker, W.K. Henry, and J.D. Neaton The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: Shifting paradigms Curr Opin HIV AIDS 4 2009 176 182
98. J.H. Stein Cardiovascular risks of antiretroviral therapy N Engl J Med 356 2007 1773 1775
99. C.K. Hoh Clinical use of FDG PET Nucl Med Biol 34 2007 737 742
100. Z. Hongming, and A. Abass 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation Semin Nucl Med 32 2002 47 59
101. J.J. Fox, and H.W. Strauss One step closer to imaging vulnerable plaque in the coronary arteries J Nucl Med 50 2009 497 500
102. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors J Inflamm (Lond) 9 2012 26
103. S. Subramanian, A. Tawakol, and T.H. Burdo Arterial inflammation in patients with HIV J Am Med Assoc 308 2012 379 386
104. A. Carr Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemaemia, and diabetes mellitus: A cohort study Lancet 353 1999 2093 2099
105. Behrens G, Stoll M, Schmidt R: Lipdosystrophy syndrome in HIV infection: What is it, what causes it and how can it be managed? Drug Saf 2000; 23: 57-76
106. G. Behrens, A. Boerner, and K. Weber Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy J Clin Invest 110 2002 1319 1327
107. C. Bleeker-Rovers, A. van der Ven, and B. Zomer F-18-Fluorodexoyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients AIDS 18 2004 2430 2432
108. M. Sathekge, A. Maes, and M. Kgomo Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET Nucl Med Commun 31 2010 311 314
109. J.M. Warwick, and M.M. Sathekge PET/CT scanning with a high HIV/AIDS prevalence Transfus Apher Sci 44 2011 167 172
110. H. Tsong Fang, A. Colantonio, and C. Uittenbogaart The role of the thymus in HIV infection: A 10 year perspective AIDS 22 2008 171 174
111. G. Hardy, S. Worrell, and P. Hayes Evidence of thymic reconstitution after highly active antiretroviral therapy in HIV-1 infection HIV Med 5 2004 67 73
112. + T cells AIDS 25 2011 1235 1237
113. + T lymphocytes in HIV-infected patients treated with interleukin-2 AIDS 13 1999 455 463
114. World Health Organization Global Tuberculosis Control Report. Surveillance Planning Financing 2009 WHO Geneva
115. M. Sathekge, and J.R. Buscombe Can positron emission tomography work in the African tuberculosis epidemic? Nucl Med Commun 32 2011 241 244
116. UNAIDS Report on the Global AIDS Epidemic 2008 UNAIDS Geneva
117. M. Mendelson Diagnosing tuberculosis in HIV-infected patients: Challenges and future prospects Br Med Bull 81-82 2007 149 165
118. J.G.W. Kosterink Positron emission tomography in the diagnosis and treatment management of tuberculosis Curr Pharm Des 17 2011 2875 2880
119. H. Zhuang, and A. Alavi 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation Semin Nucl Med 32 2002 47 59
120. 18FFDG PET for the evaluation of pulmonary nodules J Nucl Med 43 2002 871 875
121. J. Goo, H. Im, and K. Do Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases Radiology 216 2000 117 121
122. 18F-FDG PET-CT for determination of pulmonary tuberculoma activity Eur J Nucl Med Mol Imaging 35 2008 808 814
123. R. Cameron Inflammation and repair S.L. Robbins, Pathology ed 3 1967 WB Saunders Philadelphia, PA 31 37
124. D. Adams The granulomatous inflammatory response: A review Am J Pathol 84 1976 161 191
125. A. Dannenberg, and J. Tamashefski Pathogenesis of pulmonary tuberculosis A. Fishman, J. Elias, J. Fishman, Fishman's Pulmonary Disease and Disorders ed 3 1998 McGraw-Hill New York, NY 2447 2471
126. M. Cazin, D. Paluszezal, and A. Bianchi Effects of anaerobosis upon morphology and energy metabolism of alveloar macrophages cultured in gas phase Eur Respir J 3 1990 1015 1022
127. 11C-choline in lung cancer and pulmonary tuberculosis Chest 124 2003 893 901
128. 18F-FDG PET imaging for the differentiation between malignant and benign lesions Clin Radiol 63 2008 756 764
129. 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5 AJR Am J Roentgenol 191 2008 475 479
130. M.M. Sathekge, A. Maes, and H. Pottel Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area S Afr Med J 100 2010 598 601
131. WHO (World Health Organization): Global Tuberculosis Control: WHO Report. Geneva, 2011. http://www.who.int/tb/publications/global-report/en/
132. WHO (World Health Organization): Global Tuberculosis Control: surveillance, Planning, Financing. WHO Report, Geneva, 2007. http://www.who.int/tb/publications/global-report/2007/ pdf/full.pdf
133. H.M. Peto, R.H. Pratt, and T.A. Harrington Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006 Clin Infect Dis 49 2009 1350 1357
134. S. Sharma, and A. Mohan Extrapulmonary tuberculosis Indian J Med Res 120 2004 316 353
135. W. Arciniegas, and D. Orjuela Extrapulmonary tuberculosis: A review of 102 cases in Pereira, Colombia Biomedica 26 2006 71 80
136. M. Golden, and H. Vikram Extrapulmonary tuberculosis: An overview Am Fam Physician 72 2005 1761 1768
137. A. Rivas-Garcia, S. Sarria-Estrada, and C. Torrents-Odin Imaging findings of Pott's disease Eur Spine J 2012 [Epub ahead of print]
138. M. Sathekge, A. Maes, and M. Kgomo Impact of FDG PET on the management of TBC treatment. A pilot study Nuklearmedizin 49 2010 35 40
139. 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis J Nucl Med 52 2011 1 6
140. 18F]-2-fluoro-deoxy-d-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment Antimicrob Agents Chemother 53 2009 4879 4884
141. 18F- fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis Eur J Nucl Med Mol Imaging 36 2009 632 639
142. I. Park, J. Ryu, and T. Sun Shim Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography Clin Nucl Med 33 2008 1 3
143. G. Tian, Y. Xiao, and B. Chen FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis Acta Radiol 51 2010 1002 1006
144. A. Hofmeyr, E. Lau, and M. Slavin Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response Tuberculosis 87 2007 459 463
145. M. Sathekge, A. Maes, and Y. D'Asseler Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease Eur J Nucl Med Mol Imaging 39 2012 1184 1190